Common Variable Immunodeficiency (CVID)

Common variable immunodeficiency, usually called CVID, is an immune disorder in which the body fails to produce enough protective antibodies, leaving a person vulnerable to repeated infections, autoimmune problems, and other complications that can affect nearly every organ system. It is defined by low levels of immunoglobulin G (IgG) along with poor antibody responses to vaccines, distinguishing it from milder forms of antibody deficiency where vaccine responses remain intact.¹ Despite being the most frequently diagnosed symptomatic primary immunodeficiency in adults, CVID is widely under-recognized, and the gap between first symptoms and correct diagnosis remains stubbornly long.

Why Diagnosis Often Takes Years

One of the most frustrating aspects of CVID is how long people go without a diagnosis. In a New Zealand cohort study, patients who eventually developed bronchiectasis, a form of permanent airway damage, had a median diagnostic delay of 12 years. Those without bronchiectasis still waited a median of about one year, which is considerably better but still means infections pile up before treatment starts.² The same study found that this delay has not improved over time, even as awareness of immune deficiencies has grown among specialists.

The reason is partly that CVID’s early symptoms, mostly sinus infections, bronchitis, and pneumonia, look like ordinary bad luck. A person who gets pneumonia twice in three years might just be told they catch everything that goes around. Doctors who do not regularly see immunodeficiency patients may not think to check immunoglobulin levels, especially when the patient is an otherwise healthy-looking adult. Since CVID can present at any age, from childhood through middle age, there is no single demographic profile that triggers automatic suspicion.

What Goes Wrong in the Immune System

Although CVID is named for antibody deficiency, the immune breakdown goes deeper than low IgG alone. The core problem centers on B cells, the white blood cells responsible for producing antibodies. In healthy people, B cells mature through stages, eventually becoming “memory” B cells that remember past infections and “switched” B cells that produce specialized antibody types. In CVID, this maturation process stalls at different points depending on the patient.

Researchers have proposed classification systems based on how severely memory B cells are depleted. One widely referenced approach divides patients into groups depending on whether they still have switched memory B cells (the type that makes IgG and IgA). Patients with the fewest switched memory B cells tend to have the lowest IgG levels, the weakest vaccine responses, and the highest rates of autoimmune and granulomatous disease.³ A European classification splits patients into three groups: those with near-normal memory B cells, those missing switched memory cells specifically, and those with almost no memory B cells at all. In one cohort, nearly half of patients fell into the most severe group.⁴

This B-cell dysfunction also shows up practically in vaccination studies. When CVID patients received COVID-19 vaccines, researchers found that most had a dramatically weaker memory B-cell recall response compared to healthy controls. Only three out of ten CVID patients showed even a minimal response in memory B-cell assays, while all healthy participants responded.⁵ The good news from that study was that T-cell responses to vaccination were more robust, which offers at least partial protection.

T cells are not entirely spared in CVID, though. Studies have found that many CVID patients have reduced numbers of naive CD4 T cells, the type that has not yet encountered a pathogen and stands ready to learn new threats. Patients with autoimmune complications or organ-specific autoimmunity had the most severe drops in naive CD4 counts.⁶ Low CD4 counts in CVID are considered a warning sign for more complicated disease.

The Genetic Picture

For a condition as clinically well known as CVID, the genetics remain surprisingly murky. Unlike many other primary immunodeficiencies where a single gene defect explains the disease, only a small fraction of CVID cases have a clear monogenic cause. Estimates vary: one review placed the figure at roughly 2 to 10 percent of patients, while a study using whole-exome sequencing on a European cohort estimated a monogenic origin in about 15 to 24 percent of cases, identifying variants in genes like LRBA, CTLA4, NFKB1, and PIK3R1.⁷⁸

For the majority of patients without a single causative mutation, the prevailing theory is that CVID arises from a combination of multiple genetic variants interacting with environmental triggers such as infections. This polygenic or complex-inheritance model would explain why CVID sometimes clusters in families without following a clean inheritance pattern, and why onset age and severity vary so widely even among relatives.⁹ In practice, this means genetic testing can provide actionable answers for some patients, particularly those with mutations in druggable pathways like CTLA4, but for the majority, a genetic test will come back without a definitive single-gene explanation.

Infections and Lung Damage

The most common and earliest manifestation of CVID is recurrent sinopulmonary infection: sinusitis, bronchitis, and pneumonia, typically caused by encapsulated bacteria. Before the era of immunoglobulin replacement therapy, about 84 percent of CVID patients had experienced at least one episode of pneumonia.¹⁰ Each episode of pneumonia carries the risk of scarring the airways, and repeated bouts can lead to bronchiectasis, a permanent widening and damage of the bronchial tubes that makes the lungs vulnerable to further infections in a vicious cycle.

The connection between diagnostic delay and bronchiectasis is grim. The New Zealand cohort study found that patients who developed bronchiectasis had waited a median of 12 years for their CVID diagnosis, compared to about one year for those without bronchiectasis.¹¹ Every year of untreated antibody deficiency is a year of lung infections that could have been reduced. Immunoglobulin replacement cuts the rate of lower respiratory infections roughly in half, from about 0.28 episodes per patient per year to 0.16, but it cannot reverse structural lung damage that has already occurred.¹²

Autoimmune Complications

If CVID were only about infections, management would be relatively straightforward. But roughly 30 percent of patients develop autoimmune disease, according to a systematic review and meta-analysis that pooled data from multiple cohorts.¹³ This means the same immune system that is too weak to fight off bacteria is simultaneously attacking the body’s own tissues.

The most common autoimmune problems are blood-related. In a large U.S. registry of 990 CVID patients, about 10 percent had autoimmune cytopenias: conditions where the immune system destroys the body’s own blood cells. Immune thrombocytopenia (destruction of platelets) affected about 7 percent, hemolytic anemia (destruction of red blood cells) about 4.5 percent, and autoimmune neutropenia about 1 percent.¹⁴ Beyond blood cells, autoimmune problems in CVID span the gastrointestinal tract, joints, skin, and endocrine organs.¹⁵

Autoimmune disease in CVID is not just an inconvenience. It signals a more complicated clinical course. The meta-analysis found that CVID patients without autoimmunity had higher CD4 T-cell counts, suggesting that the T-cell compartment plays a role in keeping autoimmunity in check. This fits with the observation that patients with the lowest memory B-cell counts and the most T-cell abnormalities tend to develop the most autoimmune complications.

Gastrointestinal Problems

Gut symptoms affect a large proportion of CVID patients and can be among the hardest complications to manage. These range from chronic diarrhea and malabsorption to inflammatory bowel disease-like conditions. What makes CVID enteropathy particularly tricky is that biopsies often mimic other diseases. One study found the most common biopsy findings were IBD-like inflammation (in about 56 percent of samples), nonspecific chronic inflammation (47 percent), and nonspecific active inflammation (39 percent).¹⁶ Another analysis suggested that bowel biopsies in symptomatic CVID patients fall into three broad patterns: a celiac disease-like appearance, an IBD-like picture, or nodular lymphoid hyperplasia.¹⁷

The challenge is that despite looking like IBD or celiac disease under the microscope, CVID enteropathy does not always respond to the same treatments. Standard IBD drugs may help some patients and fail others. The inflammatory process in the gut is also linked to broader systemic problems: CVID patients show reduced gut microbial diversity and elevated markers of bacterial product leakage into the bloodstream, including lipopolysaccharide (LPS) and markers of immune activation.¹⁸ Some researchers have proposed that this gut barrier dysfunction and resulting low-grade endotoxemia may feed back into the systemic inflammation seen in CVID, creating a cycle of immune activation that goes well beyond the gut itself.¹⁹

Lung Disease Beyond Infection

Not all lung problems in CVID come from bacteria. A subset of patients develop granulomatous-lymphocytic interstitial lung disease (GLILD), a condition where clusters of immune cells form granulomas and infiltrate the lung tissue itself. GLILD is considered one of the more serious non-infectious complications of CVID and contributes substantially to long-term illness.²⁰

An Italian multicenter study comparing CVID patients with and without GLILD found that the two groups had strikingly different clinical profiles. The control group, CVID patients without GLILD, overwhelmingly had an infection-only phenotype (about 70 percent). The GLILD group, by contrast, was characterized by much higher rates of lymphoproliferation and autoimmune cytopenias.²¹ In other words, GLILD appears to cluster with the more complicated, non-infectious phenotype of CVID rather than representing an extension of infection-driven damage.

Cancer Risk

CVID is associated with an elevated risk of certain cancers, particularly lymphoma and gastric cancer. The connection to gastric cancer has received particular attention because CVID patients often have chronic gastric inflammation, reduced stomach acid, and higher rates of Helicobacter pylori infection, all of which are known contributors to premalignant gastric changes.²² Despite the recognized risk, routine gastric cancer screening is rarely offered to CVID patients in standard clinical practice.²³

Certain biomarkers may help identify CVID patients at higher risk for specific cancers. Reduced switched memory B cells are broadly associated with more complications, and elevated or normal IgM levels have been suggested as a potential marker for lymphoma risk.²⁴ This is an area where more standardized screening protocols could make a meaningful difference in early detection.

Immunoglobulin Replacement Therapy

The backbone of CVID treatment is immunoglobulin replacement, which supplies the antibodies the body cannot make on its own. This can be delivered intravenously (IVIG), typically every three to four weeks in a clinic, or subcutaneously (SCIG), which patients can self-administer at home on a more frequent schedule, often weekly or biweekly.

Both routes are effective at reducing infections. A systematic review and meta-analysis found no significant difference in the risk of overall infections or serious infections between IVIG and SCIG.²⁵ A direct comparison study found that patients on IVIG averaged about 2.4 courses of antibiotics per year versus about 2.2 for SCIG, a difference that was not statistically meaningful.²⁶ Earlier studies had already reached the same conclusion: no significant differences in efficacy or adverse reaction rates between the two routes.²⁷

The practical differences between IVIG and SCIG matter quite a bit to patients, though. IVIG requires regular clinic visits and can cause systemic side effects like headache, chills, and fatigue that may last a day or more. SCIG involves smaller, more frequent doses that generally cause fewer systemic reactions, though local injection-site reactions like swelling and redness are common. The subcutaneous route tends to produce slightly higher steady-state IgG trough levels because there is no dramatic peak-and-valley cycle between infusions.²⁸ For many patients, the ability to infuse at home rather than spending hours in a clinic is reason enough to prefer SCIG.

Beyond Immunoglobulin Replacement

Immunoglobulin replacement addresses the antibody deficiency but does nothing for the autoimmune, granulomatous, and lymphoproliferative complications that drive much of the morbidity in CVID. For those problems, immunologists increasingly reach for targeted immunomodulatory drugs. One of the most studied is abatacept, a drug originally approved for rheumatoid arthritis that blocks a signaling pathway involved in T-cell activation.

A clinical trial of abatacept in CVID patients with interstitial lung disease found it was generally safe and effective. Five of the eight patients who completed the protocol showed improvement by standard respiratory criteria, and lung diffusing capacity either stabilized or improved in all of them. Lung nodules improved in about 71 percent and ground-glass opacities in 57 percent, though other types of CT abnormalities were less responsive. Quality of life improved in most patients, and fatigue decreased in over half. The drug also appeared to partially correct the underlying CD4 T-cell abnormalities, with drops in markers of T-cell overactivation and a recovery in naive CD4 counts.²⁹

This is still early-stage evidence from a small trial, but it represents a shift in thinking about CVID treatment. Instead of treating only the antibody deficiency and managing complications as they arise, clinicians are beginning to target the immune dysregulation directly. For patients with monogenic forms of CVID, particularly those with CTLA4 or LRBA mutations, drugs like abatacept have a clear mechanistic rationale. For the majority without a known single-gene cause, the choice of immunomodulatory therapy remains more empirical.

Fatigue and Quality of Life

If you talk to CVID patients about what affects their daily life the most, the answer is often not infections or even autoimmune flares. It is fatigue. Studies consistently find that fatigue is the single biggest driver of reduced quality of life in CVID, outranking pain, anxiety, and even the infections themselves. A survey using a validated patient-reported outcomes tool found that fatigue, anxiety, and social participation were the domains most affected in CVID patients compared to people without the condition, with fatigue being the most statistically significant.³⁰

CVID patients score significantly lower than the general population on standardized measures of both physical and mental health functioning.³¹ Fatigue also correlates with lower rates of employment, education, and household income, suggesting it interferes not just with how people feel but with their ability to build a career and maintain financial stability. Patients receiving IVIG report higher fatigue levels than those on SCIG, which may relate to the systemic side effects that follow intravenous infusions and the phenomenon known as “wear-off,” where patients feel progressively worse in the days leading up to their next infusion as antibody levels decline.³²

The causes of fatigue in CVID are likely multiple and overlapping: chronic low-grade infection, systemic inflammation, immune activation, disrupted sleep from respiratory problems, and the psychological burden of managing a complex chronic illness. Because fatigue is so pervasive and so poorly addressed by immunoglobulin replacement alone, it remains one of the biggest unmet needs in CVID care.

The Gut Microbiome Connection

An emerging area of research focuses on the gut microbiome in CVID. Antibodies, particularly secretory IgA, play a major role in shaping the microbial communities that live in the gut. When antibody production is impaired, the ecosystem shifts. Studies have found that CVID patients have reduced microbial diversity compared to healthy controls, and this dysbiosis correlates with elevated blood levels of bacterial products like LPS, a component of bacterial cell walls that triggers inflammation when it crosses the gut barrier.³³

The hypothesis gaining traction is that a leaky gut and microbial imbalance are not just consequences of CVID but active contributors to the systemic immune activation that drives many of its complications. Elevated markers of immune activation like soluble CD14 and soluble CD25 have been found in CVID patients alongside the elevated LPS, painting a picture of an immune system in a constant state of low-level alarm. Whether targeting the microbiome through dietary changes, probiotics, or other interventions could meaningfully improve CVID outcomes is still unknown, but the research is laying groundwork for what could eventually become a complementary treatment strategy alongside immunoglobulin replacement and immunomodulatory drugs.

1
PubMed Central. Differentiation of Common Variable Immunodeficiency From IgG Deficiency ↩︎
2
PubMed Central. Bronchiectasis is associated with delayed diagnosis and adverse outcomes in the New Zealand Common Variable Immunodeficiency Disorders cohort study ↩︎
3
PubMed. Immune competence and switched memory B cells in common variable immunodeficiency ↩︎
4
PubMed. Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects ↩︎
5
PubMed Central. Impaired B Cell Recall Memory and Reduced Antibody Avidity but Robust T Cell Response in CVID Patients After COVID-19 Vaccination ↩︎
6
PubMed Central. T cell phenotypes in patients with common variable immunodeficiency disorders: associations with clinical phenotypes in comparison with other groups with recurrent infections ↩︎
7
Journal of Medical Genetics. Genes associated with common variable immunodeficiency: one diagnosis to rule them all? ↩︎
8
PubMed Central. Evaluating the Genetics of Common Variable Immunodeficiency: Monogenetic Model and Beyond ↩︎
9
PubMed Central. Exploring Monogenic, Polygenic, and Epigenetic Models of Common Variable Immunodeficiency ↩︎
10
PubMed. Respiratory disorders in common variable immunodeficiency ↩︎
11
PubMed Central. Bronchiectasis is associated with delayed diagnosis and adverse outcomes in the New Zealand Common Variable Immunodeficiency Disorders cohort study ↩︎
12
PubMed. Respiratory disorders in common variable immunodeficiency ↩︎
13
PubMed. Autoimmunity in common variable immunodeficiency: a systematic review and meta-analysis ↩︎
14
PubMed Central. Autoimmune Cytopenias and Associated Conditions in CVID: a Report From the USIDNET Registry ↩︎
15
PubMed. Autoimmunity in common variable immunodeficiency: a systematic review and meta-analysis ↩︎
16
PubMed Central. CVID Enteropathy Is Difficult To Treat and Shows a Heterogeneous Histopathology ↩︎
17
PubMed Central. Bowel Histology of CVID Patients Reveals Distinct Patterns of Mucosal Inflammation ↩︎
18
PubMed Central. Gut Microbiome and Common Variable Immunodeficiency: Few Certainties and Many Outstanding Questions ↩︎
19
PubMed. Autoimmunity and Inflammation in CVID: a Possible Crosstalk between Immune Activation, Gut Microbiota, and Epigenetic Modifications ↩︎
20
eClinicalMedicine. Diagnosis and management of granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency ↩︎
21
PubMed Central. Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) in Common Variable Immunodeficiency (CVID) ↩︎
22
PubMed Central. Common Variable Immunodeficiency and Gastric Malignancies ↩︎
23
PubMed. Gastric Cancer Screening in Common Variable Immunodeficiency ↩︎
24
PubMed Central. Seeking Relevant Biomarkers in Common Variable Immunodeficiency ↩︎
25
PubMed Central. Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases ↩︎
26
Annals of Allergy, Asthma & Immunology. Efficacy and subcutaneous immunoglobulin versus intravenous immunoglobulin in patients with common variable immunodeficiency ↩︎
27
PubMed. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy ↩︎
28
PubMed Central. Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases ↩︎
29
PubMed. Abatacept Use Is Associated with Steroid Dose Reduction and Improvement in Fatigue and CD4-Dysregulation in CVID Patients with Interstitial Lung Disease ↩︎
30
PubMed. PROMIS-29 survey confirms major impact of fatigue on health-related quality of life in common variable immunodeficiency ↩︎
31
PubMed Central. Health-Related Quality of Life in Adult Patients with Common Variable Immunodeficiency Disorders and Impact of Treatment ↩︎
32
PubMed Central. Fatigue and the wear‐off effect in adult patients with common variable immunodeficiency ↩︎
33
PubMed Central. Gut Microbiome and Common Variable Immunodeficiency: Few Certainties and Many Outstanding Questions ↩︎